As investors have been concerned over the loss of COSTCO contract, Sonova’ share price performance has been uninspiring this year. Furthermore, the FY24 guidance was not able to meet the market’s expectations. Nevertheless, the firm’s strong legacy virtues remain intact, backed by promising offerings, reassuring stakeholder return metrics and balance sheet strength. Overall, with the improving hearing aids market environment, Sonova is attractive at the current share price levels.
